Cannara Biotech Inc.

Total Valuation

Cannara Biotech Inc. carries a market capitalization of 128.42M, placing it among publicly traded companies globally. Its enterprise value stands at 178.54M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Cannara Biotech Inc. currently has 98.78M shares outstanding.

Valuation Ratios

Cannara Biotech Inc. trades at a trailing price-to-earnings ratio of 15.04. The price-to-sales ratio is 1.39, and the price-to-book ratio stands at 1.46.

Enterprise Valuation

On an enterprise value basis, Cannara Biotech Inc. trades at an EV/EBITDA multiple of 7.11 and an EV/FCF ratio of 5.14. The EV/Sales ratio of 1.52 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 9.72 provides insight into valuation relative to core operating earnings.

Financial Position

Cannara Biotech Inc. maintains a current ratio of 3.00, meaning it holds 3.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 29.40, indicating elevated leverage, while an interest coverage ratio of 10.44 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Cannara Biotech Inc. posts a return on equity of 10.94 and a return on invested capital of 7.44.

Taxes

Over the trailing twelve months, Cannara Biotech Inc. has paid 5.42M in income taxes, reflecting an effective tax rate of 33.28.

Stock Price Statistics

Cannara Biotech Inc.'s stock has declined approximately -1.51515% over the past 52 weeks. The 50-day moving average sits at 1.23, while the 200-day moving average is 1.27.

Income Statement

Over the trailing twelve months, Cannara Biotech Inc. generated 117.33M in revenue and converted that into 10.86M in net income, yielding earnings per share of 0.11. EBITDA reached 25.11M, while operating income came in at 18.36M.

Balance Sheet

Cannara Biotech Inc. holds 21.81M in cash and equivalents against 37.00M in total debt, resulting in a net debt position of 15.01M. Total book value stands at 111.82M, with working capital of 65.12M providing operational flexibility.

Cash Flow

Cannara Biotech Inc. produced 19.42M in operating cash flow over the past twelve months. After subtracting -13.72M in capital expenditures, free cash flow totaled 5.69M - equivalent to 0.06 per share.

Margins

Cannara Biotech Inc. operates with a gross margin of 42.59, reflecting its pricing power and cost economics. The operating margin of 15.65 and net profit margin of 9.25 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Cannara Biotech Inc.'s most recent stock split took place on February 13, 2023 with a 10:1 split ratio.

Scores

Cannara Biotech Inc. posts an Altman Z-Score of 2.82, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.